Better Therapeutics Analysis
Better Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Better Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Better Therapeutics is worth, separate from its market price. There are two main types of Better Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Better Therapeutics otc stock is traded in the USA on OTCMKTS Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Better |
Better OTC Stock Analysis Notes
About 53.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.1. Better Therapeutics had not issued any dividends in recent years. Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.The quote for Better Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Better Therapeutics please contact Frank Karbe at 415 887 2311 or go to https://www.bettertx.com.Better Therapeutics Investment Alerts
| Better Therapeutics is not yet fully synchronised with the market data | |
| Better Therapeutics has some characteristics of a very speculative penny stock | |
| Better Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (31.57 M) with loss before overhead, payroll, taxes, and interest of (674 K). | |
| Better Therapeutics currently holds about 29.68 M in cash with (26.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Roughly 53.0% of the company shares are held by company insiders |
Better Therapeutics Upcoming and Recent Events
Earnings reports are used by Better Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Better Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Better Therapeutics's market, we take the total number of its shares issued and multiply it by Better Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Better Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Better Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Better Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Better Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Perry David P over a year ago Acquisition by Perry David P of 839895 shares of Better Therapeutics subject to Rule 16b-3 | ||
Perry David P over a year ago Acquisition by Perry David P of 1471453 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over a year ago Acquisition by Miller Leslie A of 3587 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over a year ago Better Therapeutics exotic insider transaction detected | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 137005 shares of Better Therapeutics | ||
Lavizzomourey Risa J over a year ago Acquisition by Lavizzomourey Risa J of 15000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Mark Heinen over a year ago Acquisition by Mark Heinen of 54000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 242424 shares of Better Therapeutics |
Better Therapeutics Outstanding Bonds
Better Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Better Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Better bonds can be classified according to their maturity, which is the date when Better Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Better Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance |